Tiltbio
Helsinki, FI · Founded 2013 · 1 known investors
TILT Biotherapeutics develops an investigational adenoviral immunotherapy platform for treating solid tumor cancers, with late-stage development of TILT-123 for head and neck cancer treatment. The company operates as a holding structure with distinct spin-out entities focused on clinical development and preclinical research.
BiotechHealthtechMedical Devices
Founders & leadership
Tiltbio was founded in 2013 by Akseli Hemminki.
AH
Akseli HemminkiFounder and CEO
Investors · 1
Funding
SEC filings, press & company announcements$25M disclosed across 1 round · 2025
- $25MSeries BMay 2025 · 2 sourcesSource ↗
Source: company announcements and press reports — follow each round's link for the claim.
Competitors · 1
by search overlap
Companies competing with Tiltbio for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Tiltbio do?
- TILT Biotherapeutics develops an investigational adenoviral immunotherapy platform for treating solid tumor cancers, with late-stage development of TILT-123 for head and neck cancer treatment. The company operates as a holding structure with distinct spin-out entities focused on clinical development and preclinical research.
- Who founded Tiltbio?
- Tiltbio was founded by Akseli Hemminki in 2013.
- Who are Tiltbio's investors?
- Tiltbio's investors include Lifeline Ventures.
- How much funding has Tiltbio raised?
- Tiltbio has disclosed $25M raised across 1 round.
- Where is Tiltbio headquartered?
- Tiltbio is headquartered in Helsinki, FI.